DOCKING STUDIES OF AMINOHYDANTOIN DERIVATIVES AS ANTIMALARIAL AGENTS
Objective: Docking studies of aminohydantoin derivatives as antimalarial agents. A novel derivative of aminohydantoins was selected from the literature. Method: in-silco studies using docking methodology. The compounds were sketched and energy minimized using Chem draw ultra and Chem 3D ultra respectively. Further, the compounds were docked into Plasmodium falciparum transferase inhibitor (3L7) using Molegro Virtual Platform. Twenty eight compounds were docked into the active site of Pf-lactate dehydrogenase cavity and all of them found to have similar binding interactions of a co-crystalized ligand. Result: The compounds were showed good docking score like moldock score and re-rank score. The finding of docking studies shows a typical molecular interaction pattern with lactate dehydrogenase. The binding interaction information derived from these molecules will be useful in future antimalarial agent design. Conclusion: From the docking study, it was observed that ligands bind to the electrostatic, hydrophobic clamp formed by the residues Asp 76(B), Tyr 190(B), Tyr 80(B) and Lys 72(B) which play an important role for Plasmodium falciparum inhibition. The binding affinity, grid calculation and RMSD percentage lower and upper parameters were calculated. Hence, the observable data indicated that, above compounds can serve as good leads for further modification and optimization in the of treatment malaria.
Keywords: Molegro, Chemdraw, aminohydantoins and docking, studies as Plasmodium falciparum, 4RAO, moldock score.
2. Krogstad D.J, Guerrant R.L, Walker D.H, Weller P.F. et al. (1999) (Eds.), Tropical Infectious Diseases Principles, Pathogens, & Practice, vol. 1, Churchill Livingstone, Philadelphia, PA, USA: 736-766.
3. Service M, Townson H, Gilles H. et al. (2002) The anopheles vector Essential Malariology, Arnold, London, UK., 59-84.
4. Gurarie D, Zimmerman P.A, King C.H, et al. (2006) Dynamic regulation of single- and mixed-species malaria infection: insights to specific and non-specific mechanisms of control, J. Theor. Biol., 240, 185-199.
5. Mayxay M, Pukrittayakamee S, Newton P.N, et al. (2004) Mixed-species malaria infections in humans, Trends Parasitol., 20, 233-240.
6. Zimmerman P.A, Mehlotra R.K, Kasehagen L.J, et al. 2004 why do we need to know more about mixed Plasmodium species infections in humans? Trends Parasitol., 20, 440-447.
7. Service M, Townson H, Gilles H, et al. (2002) The anopheles vector Essential Malariology, Arnold, London., UK, 59-84.
8. Singh. K, Okombo. J, Brunschwig. C, et al. (2017) Antimalarial Pyrido[1,2‑a] benzimidazoles: Lead Optimization, Parasite Life Cycle Stage Profile, Mechanistic Evaluation, Killing Kinetics, and in Vivo Oral Efficacy in a Mouse Model. J. Med. Chem., 60, 1432−1448.
9. Keurulainen. L, Vahermo. M, Puente-Felipe. M, et al. (2015) A Developability-Focused Optimization Approach Allows Identification of in Vivo Fast-Acting Antimalarials: N‑[3-[(Benzimidazol-2-yl)amino]propyl]amides. J. Med. Chem., 58, 4573−4580.
10. Sharma. N, Krishnan. D.M, Shard. A, et al. (2012) Stilbene - Chalcone Hybrids: Design, Synthesis, and Evaluation as a New Class of Antimalarial Scaffolds That Trigger Cell Death through Stage Specific Apoptosis. J. Med. Chem., 55, 297−311.
12. Dianne T. K, Dana H , Zlatko J, et al. (2015) Aza-acyclic Nucleoside Phosphonates Containing a Second Phosphonate Group As Inhibitors of the Human, Plasmodium falciparum and vivax 6‑Oxopurine Phosphoribosyl transferases and Their Prodrugs As Antimalarial Agents. J. Med. Chem., 58, 827−846.
13. Michael S. M, Jim E, Iwan G, et al. (2010) Design and Synthesis of 5,5-Disubstituted Aminohydantoins as Potent and Selective Human β-Secretase (BACE1) Inhibitors. J. Med. Chem., 53, 1146–1158.
14. Michael S. M, Albert R, Jim E, et al. (2010) Design and synthesis of aminohydantoins as potent and selective human b-secretase (BACE1) inhibitors with enhanced brain permeability. Bioorg. Med. Chem. Lett., 20, 6597–6605.
15. Cantana C. and Pieter S. F. W. (2007) Novel Customizable Scoring Functions Parameterized Using N-PLS, for Structure-Based Drug Discovery. J. Chem. Inf. Model., 47, 85–91.
16. Introduction to Molegro Virtual Docker, user manual MVD (2008).3.0 for Windows (www.molegro.com).
17. Rangappa. S. K, Asha. H, Srinivasa. B, et al. (2015) Comprehensive Review in Current Developments of Benzimidazole-Based Medicinal Chemistry. Chem. Bio. & D. Design., 86, 19–65.
18. Muegge I and Martin Y. C. A. (1999) general and fast scoring function for protein ligand interactions: a simplified potential approach. J. Med. Chem., 42, 791-804.
19. RCSB Protein Data Bank. URL, (http://www.rcsb.org).
20. Marvin M. J, Micky T. D, Jing X, et al. (2014) Evaluation of Aminohydantoins as a Novel Class of Antimalarial Agents. ACS Med. Chem. Lett., 5, 89−93.
21. CS Chem Office, (2008) Cambridge Soft Corporation. Version 8.0, Software Publishers Association, 1730 Mstreet, NW, Suite 700, Washington, DC. 20036, 452.
22. Gong F, Liu H, Li J, et al. (2014) Peroxiredoxin 1is involved in disassembly of flagella andcilia. Biochem Biophys Res Commun., 444, 420–426.
23. Keough, D.T, Hockova. D, Janeba. Z, et al. (2015) Aza-acyclic Nucleoside Phosphonates Containing a Second Phosphonate Group as Inhibitors of the Human, Plasmodium falciparum and vivax 6-Oxopurine Phosphoribosyl transferases and Their Prodrugs As Antimalarial Agents. J. Med. Chem. 58, 827-846.
24. Young H. P, Sunuk K, Bo-kyoung L, et al. (2013) Prx I Suppresses K-ras-Driven Lung Tumorigenesis by Opposing Redox-Sensitive ERK/Cyclin D1 Pathway. Antioxid Redox Signal. 19, 482–96.
25. Ooms F. (2000) Molecular modeling and computer aided drug design. Examples of their applications in medicinal chemistry. Curr Med Chem. 7, 141-58.
26. Pedro F and Hui L. (2010) A Systematic Review on Computer-Aided Drug Design: Docking and scoring. J Macao Polytechn Inst. 47-51.
27. Clemente J.C, Govindasamy L, Madabushi A, et al. (2006) Structure of the aspartic protease plasmepsin 4 from the malarial parasite Plasmodium malariae bound to an allophenylnorstatine-based inhibitor. Acta Crystallogr D Biol Crystallogr. Mar; 246-256.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (SeeÂ The Effect of Open Access).